In Brief
Junín virus (JUNV) causes lethal human hemorrhagic fevers treated with survivor plasma containing neutralizing antibodies. Mahmutovic et al. report the structure of the JUNV glycoprotein in complex with a neutralizing antibody and serological studies with survivor plasma, which reveal that the receptor-binding site of the viral glycoprotein is an antibody target.
INTRODUCTION
Arenaviruses are enveloped viruses that carry single-stranded, bi-segmented RNA genomes. They include viruses found in captive alethinophidian snakes (the reptarenaviruses) and viruses that circulate mostly in rodents (the mammarenaviruses) (Radoshitzky et al., 2015) . The mammarenaviruses are divided into two groups-Old World and New World-based on their serology and geographic distribution. They cause acute human viral hemorrhagic fevers with high case fatality rates (Paessler and Walker, 2013) . The pathogenic Old World mammarenaviruses include Lassa (LASV) and Lujo (LUJV) viruses (Briese et al., 2009; Charrel and de Lamballerie, 2003) . The New World mammarenaviruses include Junín (JUNV), Machupo (MACV), Guanarito (GTOV), and Sabiá (SBAV) viruses, which cause Argentine (AHF), Bolivian, Venezuelan, and Brazilian hemorrhagic fever, respectively (Charrel and de Lamballerie, 2003; Oldstone, 2002; Salas et al., 1991) . The most recently described member, Chapare virus (CHPV), was isolated from a small outbreak in Bolivia from 2003 to 2004 (Delgado et al., 2008) . All cause severe human disease associated with hemorrhage and hemodynamic shock. AHF is unique among viral hemorrhagic fevers because infusion of polyclonal neutralizing antibody-containing immune plasma derived from survivors (passive immunity) is a well-established means of treating acute human infection; when provided within 8 days of illness, it decreases the case fatality rate from 15%-30% to less than 1% (Maiztegui et al., 1979; Ruggiero et al., 1986) . For it to be effective, the immune plasma has to be administered in defined doses of neutralizing activity (Enria et al., 1984) , suggesting that antibody-mediated virus neutralization is its main mode of action.
The mammarenavirus surface envelope glycoprotein (GPC) is the target of neutralizing antibodies. GPC comprises three noncovalently associated polypeptides: the stable signal peptide (SSP), GP1, and GP2 (Burri et al., 2012) . GP1 binds cellular receptors, and GP2 contains a transmembrane segment and promotes fusion of the viral and host cell membranes. The ubiquitously expressed iron-uptake protein TfR1 is a cellular receptor for all New World hemorrhagic fever mammarenaviruses (Helguera et al., 2012; Radoshitzky et al., 2007) . TfR1 orthologs from the natural hosts of all tested clade B New World mammarenaviruses are receptors for their corresponding virus, but only the New World mammarenaviruses that cause human disease bind human TfR1 (Choe et al., 2011) .
We previously determined the structure of a MACV GP1-TfR1 complex (Abraham et al., 2010) . MACV GP1 binds TfR1 through an extensive network of contacts with the lateral surface of the apical domain of TfR1. Sequence comparison for the five New World hemorrhagic fever mammarenavirus GP1s show these to be complementary to the same TfR1 surface. A pocket on GP1 that accepts a tyrosine on the bII-2 strand of the TfR1 apical domain (Tyr211 TfR1 ) is a central feature of the GP1 receptorbinding site (RBS) (Abraham et al., 2010) . This tyrosine is present on all the TfR1 orthologs that support entry of New World mammarenaviruses and is a critical determinant of host specificity (Abraham et al., 2009; Radoshitzky et al., 2008) . GD01-AG02 (GD01) and QC03-BF11 (QC03) are antibodies that were generated in mice by immunization with inactivated JUNV (Sanchez et al., 1989) . They belong to a small group of described monoclonal antibodies that neutralize JUNV, and they are active against infectious virus (Sanchez et al., 1989) ; their epitopes have not previously been characterized. To understand how antibodies neutralize JUNV, we determined the X-ray crystal structure of JUNV GP1 complexed with the antigen-binding fragment (Fab) of GD01. The structure reveals that the antibody and receptor have similar modes of GP1 recognition and that the antibody's complementarity-determining region (CDR) H3 mimics the Tyr211 TfR1 receptor contact. GD01 and QC03 compete for the same GP1 surface, suggesting that both antibodies neutralize the virus by a similar mechanism. We further show that survivor immune plasma with neutralizing activity contains antibodies that target the Tyr211 TfR1 pocket and GP1 RBS. The GP1 RBS is thus an accessible target for therapeutics and vaccines to limit infection caused by this important group of emerging human pathogens.
RESULTS

Complex of JUNV GP1 with GD01
Because GP1 is expected to be the most membrane-distal subunit of GP on the virion surface, we tested GD01 and QC03 Fabs for JUNV GP1 reactivity. QC03 and GD01 both bound JUNV GP1 with high affinity, as measured by surface plasmon resonance (1.5 nM and 12.5 nM, respectively; Figure S1 and Table S1 ). We proceeded to determine the structure of a GP1-neutralizing antibody complex. A complex of JUNV GP1 with the GD01 Fab crystallized in space group P2 1 2 1 2 1 . We used molecular replacement with MACV GP1 (Abraham et al., 2010) and an unrelated Fab (Aoki et al., 2009 ) as search models and refined the structure with data extending to 1.8 Å (Figure 1 and Table S2 ).
The interface of JUNV GP1 with GD01 includes contacts from heavy-chain CDRs 1, 2, and 3 and light-chain CDRs 1 and 3, with the bulk of the interactions focusing on GP1 loops 3 and 7 (Figure 1) . The tyrosine-rich CDR H3 projects into a shallow cavity created by the curvature of the central b sheet and loop 3 (Figure 2, upper left panel) , which is sandwiched between the heavy-chain and light-chain CDRs. CDRs H1 and H2 form a Shared Mode of Antibody and Receptor Recognition JUNV GP1 is very similar to MACV GP1 (RMSD of 1.35 Å for Ca positions for residues 87-219 and 223-227), as expected from their sequences (48% identical for GP1 residues 87-235). The only substantial difference is loop 10, in which MACV GP1 has a disulfide-linked insert with respect to JUNV ( Figure 3A , left panel). Because of this similarity, we can superpose the JUNV GP1 and MACV GP1-TfR1 structures to predict a TfR1 footprint on JUNV GP1 (Figures 3A, right panel, 3B). All but one of the 13 residues in that footprint are within the contact zone of the antibody, which includes a total of 15 residues ( Figure S2A ).
When viewed from the perspective of GP1, the lateral surface of the TfR1 apical domain presents two parallel ridges: one formed by the edge of the aII-2 helix and the bII-6-bII-7a loop and the other by the bII-2 strand ( Figure 3C ). GP1 loop 3 fits between both ridges and crosses to the far side of the aII-2 helix. The antibody likewise presents two parallel ridges that accept GP1 loop 3-one from the heavy chain (parts of CDR H1, CDR H2, and CDR H3) and the other from the light chain (CDR L1 and CDR L3)-but are closed off at one end by the C-terminal side of CDR H2. These two ridges superpose approximately onto the receptor bII-2 sheet and aII-2 helix ridges, respectively. The antibody thus resembles the receptor in the overall shape of its CDR surface.
The GP1-Tyr211 Pocket Close examination of the antibody-GP1 interface reveals that GD01 Tyr98 (Kabat numbering scheme) in CDR H3 fits precisely into the position occupied in the receptor-glycoprotein complex by Tyr211 TfR1 , even though most of the other specific interactions are different in character (Figures 4A and 4B) . For example, the contact that MACV GP1 Ser113 forms with the hydroxyl group of Tyr211 TfR1 is replaced by a contact that Asp113 in JUNV GP1 makes with the hydroxyl group of GD01 Tyr98. Another change at position 216, where lysine in JUNV GP1 replaces a threonine in MACV GP1, prevents the tyrosine side chain from reaching more deeply into the pocket. The orientation of Tyr98 in the GD01-GP1 complex is probably one that would be observed for Tyr211 TfR1 in an authentic JUNV GP1-TfR1 complex, with CDR H3 of the antibody mimicking an important receptor contact.
We generated a modified JUNV GP1 (designated JUNV GP1 mut ), in which we occluded the GP1 pocket that accepts Tyr211 TfR1 by substituting residues that line it with bulkier ones (S111Y, I115W, and V117Y; Figure S2B ). JUNV GP1 mut expressed well in the supernatant of transfected HEK293T cells and, when purified, eluted from a size exclusion column at the same retention volume as wild-type GP1, suggesting that this mutant protein is properly folded ( Figure S2C ). As expected from the structure, GD01 did not bind JUNV GP1 mut ( Figure S2D , left panel). QC03, another JUNV neutralizing antibody, did bind JUNV GP1 mut , but considerably more weakly than it did the WT protein ( Figure S2D , right panel), suggesting that it likewise contacts the Tyr211 TfR1 pocket, but probably less centrally than does GD01. QC03 Fab competed with GD01 for binding to JUNV GP1, confirming that both GD01 and QC03 are RBSdirected antibodies ( Figure S2E ). Therefore, both neutralizing antibodies probably neutralize JUNV by interfering with binding to the host cell receptor.
RBS-Directed Antibodies in Survivor Plasma
Because survivor plasma transfusion is a very effective treatment for AHF (Enria et al., 1984; Maiztegui et al., 1979) , we The GD01 variable heavy (V H ) and variable light (V L ) interacting segments are shown along with JUNV GP1 in ribbon diagram with a semi-transparent surface representation. The color scheme is as in Figure 1 . Top left: CDR H3 includes a cluster of three tyrosines that fit into a shallow groove on the concave face of GP1. Bottom left: CDRs H1 and H2 form a network of polar contacts with GP1 loop 7 and the C-terminal end of loop 3. Top right: CDR L1 contacts the conserved GP1 Asn178 glycan. Bottom right: CDR L3 provides additional contacts to GP1 loop 3. The asterisk indicates a potential glycan for which we could not observe density.
sought to determine if immune plasma samples used for passive immunity contain RBS-directed antibodies. We obtained nine survivor plasma samples (AHF1-AHF9) with neutralizing antibody titers ranging from 1:10,240 to 1:40 and also obtained a survivor plasma sample with no neutralizing activity at the time of collection (AHF10) ( Figure 4A ). Purified survivor IgG bound , and H3 form two ridges (shown in red) that the antibody presents to GP1. Tyr98 from the antibody heavy chain is shown as sticks. Right panel: TfR1 also presents two ridges to GP1 (shown in red) formed by the helix aII-2, the bII-2 strand, and loop bII-6-bII-7a in its apical domain. Tyr211 in the bII-2 strand of the receptor is shown as sticks. JUNV GP1, as measured by ELISA, with affinities that roughly correlated with their neutralizing activities ( Figure S3 ). To determine if the Tyr211 TfR1 pocket is a target for antibodies in human immune plasma, we tested survivor IgG for binding to JUNV GP1 and GP1 mut . IgG purified from the plasma of AHF1-AHF9 IgGbound JUNV GP1 mut more weakly than they bound to WT GP1 ( Figure 4B) . The difference was less marked for lower activity AHF8 and AHF9 IgG. Survivor IgGs (particularly those with high neutralizing activity) therefore contain antibodies that bind the GP1 Tyr211 TfR1 pocket.
Although the Tyr211 TfR1 pocket is a central feature of the GP1 RBS, it is only a small part of the predicted TfR1 footprint (Figure S2B) . Some antibodies that recognize nearby sites in the large RBS, but not the pocket itself, may also have neutralizing activity. Because the GD01 footprint encompasses the entire GP1 RBS, we tested the most potent survivor IgGs for reactivity against the GD01 epitope using a competition ELISA. IgG isolated from the plasma of AHF1-AHF5, but not a control antibody (17b), competed with GD01 for binding to JUNV GP1 ( Figure 4C ). These data confirm that the RBS epitope is a target for antibodies generated during natural human infection.
DISCUSSION
Several enveloped RNA viruses cause human viral hemorrhagic fevers, but passive immunotherapy has been rigorously shown to be effective in humans only for the treatment of JUNV infection. Our findings reveal that the large RBS with which the New World hemorrhagic fever mammarenaviruses engage their obligate cell surface receptor, TfR1, is readily accessible to neutralizing antibodies. We propose that RBS accessibility explains the success of convalescent-phase plasma therapy against JUNV and that the approach could be readily deployed and adapted to limit natural outbreaks of the related New World mammarenaviruses MACV, GTOV, CHAPV, and SBAV, all of which depend on TfR1 for cellular entry (Radoshitzky et al., 2007) .
The lack of complete competition of GD01 with survivor IgGs in the ELISA shown in Figure 4C suggests that antibodies binding epitopes other than the GP1 RBS are present in survivor plasma. While antibodies that target the RBS with reasonable affinity should, in principle, be neutralizing, non-neutralizing antibodies may bind other epitopes in GP1. Potential non-neutralizing epitopes include GP1 surfaces involved in oligomerization that are accessible on soluble GP1, but not accessible on functional, trimeric GPC on the virion surface. These non-neutralizing antibodies could have been generated against shed JUNV GP1; GP1 shedding has been described in acute infection by another mammarenavirus, LASV (Branco et al., 2010) .
Receptor mimicry is a recurring phenomenon in antibody neutralization of enveloped RNA viruses. Receptor-mimicking antibodies neutralize influenza viruses (Schmidt et al., 2015; Xu et al., 2013) and HIV-1 (Scheid et al., 2011; Zhou et al., 2010) . The results here reinforce the concept that host receptor mimicry is a general mode of antibody neutralization for diverse families of viruses.
GD01 does not neutralize the other New World hemorrhagic fever mammarenaviruses ( Figure S4 ). Sequence differences in the GP1 RBS probably block binding to GD01 but preserve its interaction with TfR1. These differences result in part from long-term co-adaptation of viruses with their natural rodent hosts, including an ''arms race'' between the various rodent TfR1 orthologs and the mammarenavirus GP1s (Demogines et al., 2013) . The lateral edge and tip of the TfR1 apical domain ( Figures 3A and 3C , right panels), a site engaged by all New World mammarenaviruses, is a ''hot spot'' for mutations with strong evidence of selective pressure in rodents (Demogines et al., 2013) . A large RBS may allow GP1 to tolerate variation in host receptor sequences in a virus-host arms race, but also leaves it exposed for immune recognition. Neutralizing antibodies targeting this site could then more readily select for viral escape mutations and thus account for RBS diversity as New World mammarenaviruses circulate in their respective rodent hosts.
Because GD01 and TfR1 recognize GP1 similarly, our structure could serve as a template for in vitro or in silico design of antibodies that more faithfully mimic the receptor and neutralize some or all of the other viruses in this group. For example, the relatively prominent CDR H3 (17 residues) of GD01 projects substantially farther from the contact surface with GP1 than does the bII-2 strand of TfR1, and residues at its tip would collide with the MACV GP1-specific loop 10 insert ( Figure 4B ). An engineered antibody with a similar contact surface but a shorter CDR H3 might in principle neutralize both JUNV and MACV.
A less-accessible RBS might explain why treatment with convalescent-phase survivor plasma may be less effective against other viral hemorrhagic fevers. In the GP of the filoviruses Ebola virus (EBOV) and Sudan virus, for example, the GP1 RBS is hidden beneath a heavily glycosylated mucin-like domain that contains both O-linked and N-linked carbohydrates and becomes exposed only after this domain has been cleaved by cathepsin in acidified endosomes (Chandran et al., 2005; Lee et al., 2008) . Neutralizing antibodies that target other sites, such as the GP1-GP2 interface (which lies near the viral membrane), appear to have a larger role in limiting these infections (Dias et al., 2011; Murin et al., 2014) . The GP1 RBS for another filovirus that causes human hemorrhagic fevers, Marburg virus (MARV), is more exposed, and antibodies binding this site may be more important in controlling infection by this virus . A MARV neutralizing antibody that probably mimics a viral glycoprotein-receptor contact has been described Hashiguchi et al., 2015) .
Like filoviruses, mammarenaviruses that are endemic to South America all lack adequate and rapidly scalable treatment options. Antibodies like GD01 could eventually replace immune plasma in the treatment of AHF and perhaps of other New World hemorrhagic fevers. Our findings further suggest that a recombinant GP1 subunit-based immunization strategy, which focuses the immune response on the RBS by hiding other sites, could be effective in protecting against infection caused by these lethal agents.
EXPERIMENTAL PROCEDURES Cells and Plasmids
We maintained HEK293T (human embryonic kidney cells, ATCC CRL-1268) in DMEM supplemented with 10% (v/v) fetal bovine serum (FBS) and maintained GnTI À/À 293S cells in serum-free medium (FreeStyle 293 Expression Medium, Life Technologies). GP-expressor plasmids for JUNV, MACV, GTOV, SBAV, CHPV, TCRV, and LASV, and an expressor plasmid for vesicular stomatitis virus (VSIV) G, have been previously described (Abraham et al., 2009; Radoshitzky et al., 2007) (Helguera et al., 2012) . LUJV GP (GenBank: NC_023776.1) was synthesized as a codon-optimized gene for mammalian expression and subcloned into the pCAGGS vector. We obtained hybridomas producing monoclonal antibodies GD01 and QC03 (clones GD01-AG02 and QC03-BF11, respectively) (Sanchez et al., 1989 ) from the NIAID Biodefense and Emerging Infections (BEI) repository. We maintained these cells in Hybridoma-SFM expression medium (Life Technologies). We used the pHLSec vector (Aricescu et al., 2006) to express secreted glycoproteins.
Pseudotype Transduction
We packaged pseudotypes in 293T cells by transfecting plasmids encoding murine leukemia virus gag/pol, the arenaviral GP, and the pQCXIX transduction vector (BD Biosciences) expressing eGFP in a 1:1:1 ratio, as previously described (Radoshitzky et al., 2007) . We harvested virus-containing culture supernatant 24 hr and 48 hr later. We filtered supernatants through a 0.45 mm membrane and stored pseudotypes at À80 C until later use. For antibody neutralization experiments, we pre-incubated pseudotypes with polyclonal IgG or monoclonal antibodies for 30 min at 37 C. We then added the pseudotypes and antibody mixture to cells and changed the media with 10% (v/v) FBS-supplemented DMEM 3 hr post-transduction. We measured entry levels by flow cytometry 48 hr post-transduction.
Protein Expression and Purification
To generate biotinylated proteins, we subcloned JUNV GP1 (residues 87-235), MACV GP1 (residues 87-250), and LUJV GP1 (residues 59-217), along with an N-terminal His 6 -tag, followed by a Tobacco etch virus (TEV) protease site, a BirA ligase site (amino acids: GLNDIFEAQKIEWHE), and a seven residue linker (amino acid sequence: GTGSGTG) into the pHLSEC expression vector (Aricescu et al., 2006) . We generated by site-directed mutagenesis JUNV GP1 mut , which encodes JUNV GP1 residues 87-235 and contains the S111Y, I115W, and V117Y mutations. We produced proteins by transfection using linear polyethylenimine in HEK293T cells grown in suspension and purified the proteins using nickel-affinity chromatography. We removed the His 6 -tag with TEV protease and reverse nickel-affinity purification, then performed site-specific biotinylation with BirA ligase followed by size exclusion chromatography on a Superdex 200 column (GE Healthcare Sciences) to remove free biotin. For crystallography, we subcloned JUNV GP1 (residues 87-235) with the addition of N-terminal His 6 -Tag, a TEV protease site, and a short linker (amino acids: SGSG) into the pHLSEC vector. We produced the protein in GnTI À/À 293S cells grown in suspension, purified it by nickel-affinity chromatography, and removed the tag with TEV digestion, reverse nickel-affinity purification, and size exclusion on a Superdex 200 column. We produced GD01 and QC03 Fabs using a Pierce Fab Preparation Kit (Thermo Scientific) from Protein G Ultralink Resin (Thermo Scientific) following the manufacturer's protocol. JUNV GP1 and GD01 Fab, when mixed in an equimolar ratio, crystallized in mother liquor containing 24% PEG 3350 (v/v), 10 mM Tris (pH 8.0), 150 mM NaCl. We flash froze crystals in mother liquor containing 15% (v/v) glycerol for data collection.
Surface Plasmon Resonance Binding Assays
We performed binding experiments in duplicate with a Biacore 3000 (GE Healthcare Sciences), using streptavidin coated sensor chips, and biotinylated JUNV GP1. We captured approximately 610 response units of biotinylated JUNV GP1 onto the chip to avoid rebinding events. We carried out experiments in HBS-EP (10 mM HEPES [pH 7.5], 150 mM NaCl, 3 mM EDTA, and 0.005% P-20). We passed GD01 and QC03 Fabs over the surface at various concentrations and analyzed GP1-Fab interactions using multi-cycle kinetic analysis with 2 min association and 5 min dissociation phases with a flow rate of 50 ml/min. We regenerated the surface between each cycle with two 5 ml injections of 35 mM NaOH, 1.3 M NaCl at 100 ml/min, and 2 min stabilization after regeneration. For analysis, we subtracted injections over blank surfaces from the data and fit the data using a 1:1 Langmuir binding model in the BiaEvaluation software (GE Healthcare Sciences).
Data Collection and Structure Determination
The JUNV GP1-GD01 Fab complex crystallized in the P2 1 2 1 2 1 space group, with unit cell dimensions a = 52, b = 55, and c = 178. We collected X-ray diffraction data at a wavelength of 0.9789 and temperature of 100K at NE-CAT beam line ID-24C at the Advanced Photon Source (Argonne National Laboratory). We processed data using MOSFLM (Leslie and Powell, 2007) and determined the structure of the complex by molecular replacement with PHASER (McCoy et al., 2007) , with MACV GP1 (PBD: 3KAS) (Abraham et al., 2010) and the 4F8 Fab (PDB: 3FMG) (Aoki et al., 2009 ) as search models. We observed electron density for residues 87-227 for JUNV GP1, residues 1-213 with the exception of residues 128-132 in the GD01 HC, and residues 1-212 in the GD01 LC. We obtained the sequence for the GD01 Fab using a previously described protocol for antibody gene recovery from the parent hybridoma (Fields et al., 2013 ) and performed iterative model building with COOT (Emsley et al., 2010) and refinement with PHENIX (Adams et al., 2010) and BUSTER (Bricogne et al., 2011) , yielding a final R work of 18.1% and R free of 22.4% (Table S2) , with Ramachandran favored: 97.7% and Ramachandran outliers: 0.18%. We made figures with the PyMol Molecular Graphics System (Schrö dinger).
Human Immunoglobulin Purification
We obtained 5 de-identified plasma samples from Argentine hemorrhagic fever survivors from the immune plasma bank at the Instituto Nacional de Enfermedades Virales Humanas (INEVH), based in Pergamino, Argentina, where these samples are routinely stored. Provision of the previously collected survivor plasma samples was approved by the INEVH Ethics Committee and the Harvard University Faculty of Medicine Committee on Human Studies (identified as not involving human subjects under 45CFR46.102(f)). We obtained an additional five plasma survivor samples through INEVH under a Boston Children's Hospital Institutional Review Board (IRB: IRB-P00007578) and INEVH Ethics Committee approved protocol after informed consent was obtained from all subjects. Neutralizing antibody titers from the donors at the time of plasma collection had previously been determined by the fixed-virus/variable serum technique, with Vero cell monolayers infected with the XJCl 3 attenuated strain of JUNV virus and defined as a plaque neutralization reduction of 80% (PRNT 80 ). Because the heparin that is contained in the plasma samples could interfere with the interpretation of the results of the pseudotype assay, we purified IgG from these samples using Protein G Ultralink Resin (Thermo Scientific), as instructed by the manufacturer.
ELISA Experiments
We used streptavidin-coated ELISA plates (Thermo Scientific) and coated wells with biotinylated antigens at a concentration of 0.2 mg/ml in PBS containing 2% BSA. For ELISA-based competition assays, we added GD01 or 17b IgG at increasing concentrations during a pre-incubation step of 30 min, then added the AHF survivor IgG at fixed concentrations (to obtain a baseline signal of 1.5-2 OD 450 nm). We detected bound antibody with horseradish peroxidase (HRP)-coupled anti-human antibody.
ACCESSION NUMBERS
The accession number for the structure of JUNV GP1 bound to the GD01 Fab reported in this paper is PDB: 5EN2.
